Liquid Biopsy | October Round-Up 2026

November 17, 2026
Newsletter Update
Diagnostics

‍Highlights & Summary

Liquid Biopsy continued to progress in October, featuring new regulatory milestones, MRD and screening launches, ESMO study results, and notable diagnostics deal activity.

‍

Clinical and Regulatory

1 | FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay

The FDA granted Breakthrough Device Designation to Natera’s cfDNA-based MCED assay after incorporating data from 12 cancer types, considering sensitivity, specificity, and cancer signal origin (CSO) performance in their review

Breakthrough Device Designation | Natera

‍

2 | Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

Guardant360 CDx received CE marking within EU IVDR as a companion diagnostic to identify patients with ER-positive, HER2-negative locally advanced / metastatic breast cancer who may benefit from camizestrant, following approvals of the assay for the same drug in the US and Japan

CDx Approval | Guardant Health

‍

3 | Burning Rock’s OncoCompass® Target CDx Kit Enters NMPA Priority Approval Procedure

The Burning Rock Dx OncoCompass Target CDx Kit, an NGS-based liquid biopsy kit for comprehensive genomic profiling using ctDNA, entered the National Medical Products Administration (NMPA) Priority Approval Procedure for Medical Devices, paving the way for approval in China

Regulatory Pathway | Burning Rock Dx

‍

‍

Company Announcements & Product Launches

1 | Abbott launches whole-genome sequencing Oncodetect® molecular residual disease test to detect traces of cancer during and after treatment

Abbott announced the commercial availability of the next-generation Oncodetect MRD test, a personalized, tumor-informed MRD assay built on whole-genome sequencing and the Broad Institute-derived MAESTRO enrichment technology

Product Launch | Abbott

‍

2 | Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option

Freenome launched SimpleScreen Lung, a cfDNA test for adults 50 to 80 with a >20 pack-year history who are not participating in guideline-recommended screening, expanding the offering to optionally include FDA-approved SimpleScreen CRC from a single blood draw

Product Launch | Freenome

‍

3 | Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Signatera has been selected to identify MRD-positive colorectal cancer patients with no radiographic evidence of disease after curative-intent therapy for enrollment in TransCode’s Phase 2a trial of TTX-MC138, an investigational microRNA-10b inhibitor

Collaboration | Natera, TransCode Therapeutics

‍

‍

Clinical Trials & Study Results

1 | Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Alliance Foundation Trials and Natera launched the AFT-70 NAVIGATE trial, a phase III trial of more than 2,000 patients with stage II-III ER-positive/HER2-negative early breast cancer; the study tests whether patients with no detectable MRD on Signatera Genome after standard treatment can take Genentech’s investigational oral SERD giredestrant alone, adding a CDK4/6 inhibitor only if Signatera turns positive

Trial Launch | Natera, Alliance Foundation Trials

‍

2 | Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

The COSMOS-MEL01 study represents the first prospective, multicenter study of Guardant Reveal in resected melanoma, which demonstrated 81% sensitivity for recurrence and 100% post-treatment specificity, extending methylation-based MRD evidence beyond the colorectal, breast, and lung cancers where Reveal is currently offered

Study Results | Guardant Health

‍

3 | Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Abbott’s Beta-CORRECT data compared the whole-genome, MAESTRO-based Oncodetect test with the first-generation whole-exome version in colorectal cancer, with the genome version showing a sensitivity gain for recurrence within two years of surgery, supporting larger variant panels and enrichment to improve post-surgical ctDNA detection

Study Results | Abbott

‍

‍

‍

M&A | VC | Private Equity | Legal

1 | Personalis Reports Expiration of HSR Waiting Period for Proposed Merger With Tempus AI

Personalis reported in an SEC filing that the HSR waiting period for the merger with Tempus AI expired on October 2, clearing the antitrust condition; though closing still requires Personalis stockholder approval, the transaction would fold the tumor-informed NeXT Personal MRD assay into Tempus’ data and AI platform

Merger | Personalis, Tempus AI

‍

2 | QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer

EQT Private Equity agreed with QIAGEN’s boards on a recommended all-cash offer of 46.50 euros per share, a premium of about 40 percent to the pre-speculation share price

Public Takeover | EQT, QIAGEN

‍

3 | Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Myriad announced an agreement to sell its Prenatal Health business, which includes the Prequel, Foresight, SneakPeek, and FirstGene tests (including their cfDNA-based prenatal screen), to Labcorp for $210M, with closing expected by early 2027 subject to regulatory clearance

Divestiture | Myriad Genetics, Labcorp

‍

‍

‍

‍‍

Additional Sources

‍

Clinical and Regulatory

1 | Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late-stage incidence end points and post-trial ongoing evaluation—The Peachtree Consensus

MCED Trial Guidance | American Cancer Society

‍

Company Announcements & Product Launches

1 | Mammogen and MammoLink Partner to Advance Community-Based Breast Cancer Detection

Clinical Research Partnership | Mammogen, MammoLink

‍

Clinical Trials & Study Results

1 | Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

Study Results | Natera

‍

2 | Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

Study Results | Myriad Genetics

Precision Medicine is evolving at a rapid pace

Discover how we can help

Get in Touch